CN106459011B - 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途 - Google Patents

作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途 Download PDF

Info

Publication number
CN106459011B
CN106459011B CN201580029187.0A CN201580029187A CN106459011B CN 106459011 B CN106459011 B CN 106459011B CN 201580029187 A CN201580029187 A CN 201580029187A CN 106459011 B CN106459011 B CN 106459011B
Authority
CN
China
Prior art keywords
cancer
compound
use according
compounds
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580029187.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459011A (zh
CN106459011A8 (zh
Inventor
W.豪金斯
R.马赫
D.斯皮策尔
S.冯夫拉丰
B.范蒂内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN106459011A publication Critical patent/CN106459011A/zh
Publication of CN106459011A8 publication Critical patent/CN106459011A8/zh
Application granted granted Critical
Publication of CN106459011B publication Critical patent/CN106459011B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580029187.0A 2014-04-01 2015-04-01 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途 Active CN106459011B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973366P 2014-04-01 2014-04-01
US61/973,366 2014-04-01
PCT/US2015/023954 WO2015153814A1 (en) 2014-04-01 2015-04-01 Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Publications (3)

Publication Number Publication Date
CN106459011A CN106459011A (zh) 2017-02-22
CN106459011A8 CN106459011A8 (zh) 2017-06-30
CN106459011B true CN106459011B (zh) 2019-11-15

Family

ID=54241267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029187.0A Active CN106459011B (zh) 2014-04-01 2015-04-01 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途

Country Status (8)

Country Link
US (5) US10087175B2 (enExample)
EP (1) EP3126356B1 (enExample)
JP (1) JP6557253B2 (enExample)
CN (1) CN106459011B (enExample)
AU (2) AU2015240775B2 (enExample)
CA (1) CA2944069C (enExample)
ES (1) ES2743701T3 (enExample)
WO (1) WO2015153814A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3126356B1 (en) 2014-04-01 2019-07-31 Washington University Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
US11175296B2 (en) 2016-10-26 2021-11-16 Washington University Methods of diagnosing and treating cancer comprising ME1
EP3630089A4 (en) * 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
EP1848698B1 (en) * 2005-01-25 2013-03-13 Prolexys Pharmaceuticals, Inc. Quinoxaline derivatives as antitumor agents
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
JP2008537726A (ja) * 2005-01-25 2008-09-25 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 癌細胞を殺傷するためのエラスチンアナログおよびその使用
WO2006130426A2 (en) 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
AU2006330883A1 (en) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc. 3-aryl-substituted quinazolones, and uses thereof
WO2008013987A2 (en) * 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
US8324251B2 (en) * 2006-10-04 2012-12-04 Bristol-Myers Squibb Company Cyclic modulators of chemokine receptor activity
US8143222B2 (en) 2007-10-22 2012-03-27 Washington University Modular platform for targeted therapeutic delivery
EP3126356B1 (en) 2014-04-01 2019-07-31 Washington University Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Also Published As

Publication number Publication date
US10975069B2 (en) 2021-04-13
JP2017509672A (ja) 2017-04-06
US10087175B2 (en) 2018-10-02
WO2015153814A1 (en) 2015-10-08
US20190002457A1 (en) 2019-01-03
JP6557253B2 (ja) 2019-08-07
AU2015240775A1 (en) 2016-10-20
US20250145617A1 (en) 2025-05-08
EP3126356A1 (en) 2017-02-08
EP3126356B1 (en) 2019-07-31
AU2015240775B2 (en) 2019-01-03
ES2743701T3 (es) 2020-02-20
US20170015660A1 (en) 2017-01-19
EP3126356A4 (en) 2017-08-16
CA2944069C (en) 2022-03-08
US20200123149A1 (en) 2020-04-23
US10344029B2 (en) 2019-07-09
AU2019200353A1 (en) 2019-02-07
CN106459011A (zh) 2017-02-22
AU2019200353B2 (en) 2020-01-30
NZ724819A (en) 2020-09-25
CN106459011A8 (zh) 2017-06-30
CA2944069A1 (en) 2015-10-08
US20210221805A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
JP7696443B2 (ja) Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類
US20250145617A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
ES2705342T3 (es) Co-cristales de (S)-N-metil-8-(1-((2&#39;-metil-[4,5&#39;-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
ES2988261T3 (es) Formas mórficas de GIT38 y métodos de fabricación de las mismas
JP7475062B2 (ja) ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
WO2018005533A1 (en) Antiproliferative pyrimidine-based compounds
KR20230049678A (ko) 이카로스 또는 아이올로스에 의해 매개되는 장애를 위한 유리한 요법
JP6619420B2 (ja) Ｍｅｔａｐ−２阻害剤としてのピロリジノン誘導体
ES2881048T3 (es) Bisaminoquinolinas asimétricas y bisaminoquinolinas con enlazadores variados como inhibidores de la autofagia para el cáncer y otras terapias
WO2023039208A1 (en) Selected compounds for targeted degradation of brd9
ES2880999T3 (es) Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas
JP2018522838A (ja) ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール
JP2024521791A (ja) 脳又はｃｎｓへの癌転移を治療するためのｅｇｆｒデグレーダー
US20240245677A1 (en) Selected compounds for targeted degradation of brd9

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 61/973,366 2014.04.01 US

Number: 08

Volume: 33

CI01 Publication of corrected invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 61/973,366 2014.04.01 US

Number: 08

Page: The title page

Volume: 33

CI02 Correction of invention patent application
GR01 Patent grant
GR01 Patent grant